We are live on ! Find out more
DCM

Defilade Capital Management Portfolio holdings

AUM $747M
This Fund
S&P 500
This Quarter Est. Return
+5.84%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$34.8M
Cap. Flow
+$1.91M
Cap. Flow %
0.26%
Top 10 Hldgs %
46.51%
Holding
50
New
19
Increased
9
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VEEV icon
Veeva Systems
VEEV
+$39M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$37.4M
3
PODD icon
Insulet
PODD
+$29.5M
4
BAX icon
Baxter International
BAX
+$27.2M
5
ABT icon
Abbott
ABT
+$26.1M

Top Sells

Rank Stock Value
1
HSIC icon
Henry Schein
HSIC
+$46M
2
BDX icon
Becton Dickinson
BDX
+$43.9M
3
RVMD icon
Revolution Medicines
RVMD
+$34.1M
4
DXCM icon
DexCom
DXCM
+$33.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.06T
$46.9M 6.28%
39,086
+18,390
+89% +$18.8M
PFE icon
2
Pfizer
PFE
$161B
$42.7M 5.71%
1,771,743
+307,614
+21% +$8.05M
VEEV icon
3
Veeva Systems
VEEV
$39.8B
$42M 5.62%
+236,709
New +$39M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.7B
$39M 5.22%
+682,005
New +$37.4M
PTCT icon
5
PTC Therapeutics
PTCT
$6.07B
$35.4M 4.74%
433,699
+57,534
+15% +$4.15M
BAX icon
6
Baxter International
BAX
$13.7B
$31.1M 4.17%
+1,459,380
New +$27.2M
INSM icon
7
Insmed
INSM
$27.2B
$30M 4.02%
281,838
+86,929
+45% +$10.5M
ZBH icon
8
Zimmer Biomet
ZBH
$19.3B
$27.3M 3.66%
317,426
-261,735
-45% -$22.9M
PODD icon
9
Insulet
PODD
$9.94B
$26.9M 3.61%
+176,932
New +$29.5M
TMO icon
10
Thermo Fisher Scientific
TMO
$234B
$26M 3.49%
+51,934
New +$24.9M
ABT icon
11
Abbott
ABT
$197B
$25.9M 3.47%
+285,778
New +$26.1M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.4B
$25.3M 3.39%
94,843
+42,948
+83% +$10M
SOLV icon
13
Solventum
SOLV
$15.6B
$24.4M 3.27%
+316,454
New +$23.1M
MDT icon
14
Medtronic
MDT
$118B
$23.7M 3.18%
+303,301
New +$24.5M
ELAN icon
15
Elanco Animal Health
ELAN
$12.5B
$21.3M 2.85%
864,080
-67,041
-7% -$1.55M
AGIO icon
16
Agios Pharmaceuticals
AGIO
$2.03B
$20.3M 2.72%
+546,848
New +$16.6M
NVST icon
17
Envista
NVST
$4.47B
$19.1M 2.56%
+726,108
New +$18.3M
RVMD icon
18
Revolution Medicines
RVMD
$46.2B
$15.5M 2.08%
82,827
-233,145
-74% -$34.1M
ICUI icon
19
ICU Medical
ICUI
$4.49B
$15.5M 2.07%
105,700
-148,591
-58% -$19.4M
COGT icon
20
Cogent Biosciences
COGT
$6.37B
$15.2M 2.04%
393,441
+40,851
+12% +$1.43M
LNTH icon
21
Lantheus
LNTH
$6.58B
$14.7M 1.97%
132,662
-116,739
-47% -$10.9M
OCUL icon
22
Ocular Therapeutix
OCUL
$2.37B
$14.6M 1.96%
1,490,286
+2,641
+0.2% +$23.9K
ELDN icon
23
Eledon Pharmaceuticals
ELDN
$272M
$13.9M 1.86%
3,525,338
-38,789
-1% -$141K
TYRA icon
24
Tyra Biosciences
TYRA
$1.56B
$12M 1.61%
+376,870
New +$12.5M
OLMA icon
25
Olema Pharmaceuticals
OLMA
$949M
$11.6M 1.55%
924,758
-579,778
-39% -$7.77M
1
2

Similar funds

BG
BDF Gestion Paris, France $747M AUM 47.35% 1-Year Est. Return
PCM
Permanent Capital Management Chicago, Illinois $747M AUM 17.94% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $748M AUM 27.21% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $745M AUM 23.99% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
VCM
Virtue Capital Management Brentwood, Tennessee $749M AUM 40.13% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $745M AUM 25.89% 1-Year Est. Return
CCME
CIBC Capital Markets (Europe) Luxembourg $745M AUM

Defilade Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Defilade Capital Management held 50 positions worth $747M, up 4.9% from $712M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Defilade Capital Management's Q2 2026 filing shows 19 new, 9 increased, 10 reduced and 11 closed positions. Its largest new stake was Veeva Systems: 236,709 shares worth $42M. The largest sale was Henry Schein, an estimated $46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Defilade Capital Management's largest Q2 2026 buy was Veeva Systems: 236,709 shares worth $42M.
  • Defilade Capital Management added most to Eli Lilly in Q2 2026, an estimated $18.8M increase.
  • Defilade Capital Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $34.1M.
  • Defilade Capital Management fully exited Henry Schein in Q2 2026, selling an estimated $46M.
  • Defilade Capital Management's ten largest holdings make up 47% of its $747M portfolio in Q2 2026.
  • Defilade Capital Management opened 19 new positions and closed 11 in Q2 2026.
  • Defilade Capital Management's portfolio value rose 4.9% quarter-over-quarter to $747M.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.